{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:48:47Z","timestamp":1792241327030,"version":"4.4.0"},"reference-count":131,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III, Ministerio de Economia y Competividad, Spain","doi-asserted-by":"publisher","award":["PI19\/01588"],"award-info":[{"award-number":["PI19\/01588"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III, Ministerio de Economia y Competividad, Spain","doi-asserted-by":"publisher","award":["GLD19\/00121"],"award-info":[{"award-number":["GLD19\/00121"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gilead Sciences S.L., Spain","award":["PI19\/01588"],"award-info":[{"award-number":["PI19\/01588"]}]},{"name":"Gilead Sciences S.L., Spain","award":["GLD19\/00121"],"award-info":[{"award-number":["GLD19\/00121"]}]},{"name":"Josep Carreras International Foundation","award":["PI19\/01588"],"award-info":[{"award-number":["PI19\/01588"]}]},{"name":"Josep Carreras International Foundation","award":["GLD19\/00121"],"award-info":[{"award-number":["GLD19\/00121"]}]},{"name":"\u201cla Caixa\u201d Foundation","award":["PI19\/01588"],"award-info":[{"award-number":["PI19\/01588"]}]},{"name":"\u201cla Caixa\u201d Foundation","award":["GLD19\/00121"],"award-info":[{"award-number":["GLD19\/00121"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite the widespread use of combined antiretroviral therapy (cART) and the subsequent decrease in AIDS-defining cancers, HIV-related lymphomas remain a leading cause of morbidity and mortality in people with HIV (PWH). Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL) subtype in PWH. This lymphoma is a heterogeneous disease including morphological variants and molecular subtypes according to the cell of origin or the mutation profile. In the pre-cART era, treatment with standard-dose chemotherapy induced high rates of toxicity and outcomes were very poor. The introduction of cART and the incorporation of infection prophylaxis allowed the use of conventional intensive chemotherapy regimens used in the general population, such as R-CHOP or R-EPOCH. The use of cART during chemotherapy treatment was initially controversial due to the potential risk of adverse drug\u2013drug interactions. However, the availability of current cART regimens with less potential to cause drug interactions and evidence that cART improves survival rates in NHL strongly support the use of cART in PWH with DLBCL. Consequently, interdisciplinary collaboration between HIV specialists and hemato-oncologists for the management of potential interactions and overlapping toxicities between antiretroviral and antineoplastic drugs is crucial for the optimal treatment of PWH with NHL.<\/jats:p>","DOI":"10.3390\/cancers15123191","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T02:03:19Z","timestamp":1686794599000},"page":"3191","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Diffuse Large B-Cell Lymphoma in the HIV Setting"],"prefix":"10.3390","volume":"15","author":[{"given":"Maria","family":"Huguet","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Catal\u00e0 d\u2019Oncologia, Germans Trias i Pujol University Hospital, Universitat Aut\u00f2noma de Barcelona, Ctra. de Canyet, S\/N, 08916 Badalona, Spain"},{"name":"Josep Carreras Leukaemia Research Institute, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-6013","authenticated-orcid":false,"given":"Jos\u00e9-Tom\u00e1s","family":"Navarro","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institut Catal\u00e0 d\u2019Oncologia, Germans Trias i Pujol University Hospital, Universitat Aut\u00f2noma de Barcelona, Ctra. de Canyet, S\/N, 08916 Badalona, Spain"},{"name":"Josep Carreras Leukaemia Research Institute, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Molt\u00f3","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Lluita Contra les Infeccions, Infectious Diseases Department, Germans Trias i Pujol University Hospital, Ctra. de Canyet, S\/N, 08916 Badalona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1042-6024","authenticated-orcid":false,"given":"Josep-Maria","family":"Ribera","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institut Catal\u00e0 d\u2019Oncologia, Germans Trias i Pujol University Hospital, Universitat Aut\u00f2noma de Barcelona, Ctra. de Canyet, S\/N, 08916 Badalona, Spain"},{"name":"Josep Carreras Leukaemia Research Institute, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1882-0368","authenticated-orcid":false,"given":"Gustavo","family":"Tapia","sequence":"additional","affiliation":[{"name":"Department of Pathology, Germans Trias i Pujol University Hospital, Universitat Aut\u00f2noma de Barcelona, Ctra. de Canyet, S\/N, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2015-11-681411","article-title":"A lymphomagenic role for HIV beyond immune suppression?","volume":"127","author":"Dolcetti","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/j.semdp.2017.04.003","article-title":"Human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) related lymphomas, pathology viewpoint","volume":"34","author":"Fend","year":"2017","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_3","unstructured":"Centers for Disease Control and Prevention (1992). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm. Rep., 41, 1\u201319."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.2011.396","article-title":"Proportions of Kaposi Sarcoma, Selected Non-Hodgkin Lymphomas, and Cervical Cancer in the United States Occurring in Persons with AIDS, 1980\u20132007","volume":"305","author":"Shiels","year":"2011","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/djt158","article-title":"Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era","volume":"105","author":"Gopal","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3018(20)30118-1","article-title":"Epidemiology of Haematological Malignancies in People Living with HIV","volume":"7","author":"Kimani","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.7326\/M14-2768","article-title":"Cumulative incidence of cancer among persons with HIV in North America: A cohort study","volume":"163","author":"Silverberg","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1093\/cid\/ciaa1016","article-title":"Deaths Attributable to Cancer in the US Human Immunodeficiency Virus Population During 2001\u20132015","volume":"72","author":"Horner","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1097\/QAD.0b013e32833a0961","article-title":"Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy","volume":"24","author":"Chao","year":"2010","journal-title":"AIDS"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/cncr.21562","article-title":"Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Incidence, presentation, treatment, and survival","volume":"106","author":"Diamond","year":"2006","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hiv.12136","article-title":"British HIV Association Guidelines for HIV-Associated Malignancies 2014","volume":"15","author":"Bower","year":"2014","journal-title":"HIV Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrclinonc.2014.31","article-title":"Diagnosis and management of lymphomas and other cancers in HIV-infected patients","volume":"11","author":"Carbone","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3816\/CLM.2003.n.016","article-title":"Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy","volume":"4","author":"Thirlwell","year":"2003","journal-title":"Clin. Lymphoma"},{"key":"ref_14","first-page":"704","article-title":"The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy","volume":"90","author":"Navarro","year":"2005","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdv036","article-title":"Changes in the influence of lymphoma and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma","volume":"26","author":"Barta","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/QAD.0000000000000624","article-title":"HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era","volume":"29","author":"Baptista","year":"2015","journal-title":"AIDS"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood.2020005469","article-title":"Hematologic cancers in individuals infected by HIV","volume":"139","author":"Carbone","year":"2022","journal-title":"Blood"},{"key":"ref_18","unstructured":"UNAIDS (2022, November 20). Global HIV and AIDS Statistics\u20142022 Factsheet. Available online: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0140-6736(91)92513-2","article-title":"AIDS-associated non-Hodgkin lymphoma","volume":"337","author":"Beral","year":"1991","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/(SICI)1097-0215(19961211)68:6<754::AID-IJC11>3.0.CO;2-0","article-title":"Kaposi\u2019s sarcoma and non-Hodgkin\u2019s lymphoma following the diagnosis of AIDS. Multistate AIDS\/Cancer Match Study Group","volume":"68","author":"Biggar","year":"1996","journal-title":"Int. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ijc.23487","article-title":"Cancer risk in people infected with human immunodeficiency virus in the United States","volume":"123","author":"Engels","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Cancer risk in HIV-infected people in the USA from 1996 to 2012: A population-based, registry-linkage study","volume":"4","author":"Shiels","year":"2017","journal-title":"Lancet HIV"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/QAD.0000000000000163","article-title":"Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States","volume":"28","author":"Robbins","year":"2014","journal-title":"AIDS"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"ofv147","DOI":"10.1093\/ofid\/ofv147","article-title":"Malignancies, particularly B-cell lymphomas, are a frequent cause of mortality in human immunodeficiency virus-1 patients despite highly active antiretroviral therapy","volume":"2","author":"Griffin","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/QAD.0b013e3282f2705d","article-title":"Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy","volume":"22","author":"Polesel","year":"2008","journal-title":"AIDS"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.beha.2012.01.005","article-title":"EBV-associated lymphomas in adults","volume":"25","author":"Roschewski","year":"2012","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood-2008-09-180315","article-title":"HIV-associated lymphomas and gamma-herpesviruses","volume":"113","author":"Carbone","year":"2009","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: A meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/QAD.0000000000000428","article-title":"Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: A population-based study","volume":"28","author":"Gibson","year":"2014","journal-title":"AIDS"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1093\/cid\/cit497","article-title":"Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: Results from the FHDH-ANRS CO4 cohort","volume":"57","author":"Hleyhel","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.bjc.6605756","article-title":"Changing patterns of cancer incidence in the early- and late-HAART periods: The Swiss HIV Cohort Study","volume":"103","author":"Franceschi","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/hiv.12034","article-title":"Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of northern Italy, 1999\u20132009","volume":"14","author":"Calabresi","year":"2013","journal-title":"HIV Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/ijc.30154","article-title":"Record linkage to correct under-ascertainment of cancers in HIV cohorts: The Sinikithemba HIV clinic linkage project","volume":"139","author":"Sengayi","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/ijc.21443","article-title":"Spectrum of cancers among HIV-infected persons in Africa: The Uganda AIDS-Cancer Registry Match Study","volume":"118","author":"Mbulaiteye","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2141.2006.06464.x","article-title":"Modern management of non-Hodgkin lymphoma in HIV-infected patients","volume":"136","author":"Mounier","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S2352-3018(18)30360-6","article-title":"Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: A multicentre cohort study","volume":"6","author":"Qin","year":"2019","journal-title":"Lancet HIV"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.14073","article-title":"Trends in primary central nervous system lymphoma incidence and survival in the U.S","volume":"174","author":"Shiels","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1200\/JCO.2008.20.5450","article-title":"Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034","volume":"27","author":"Chadburn","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","article-title":"The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma","volume":"115","author":"Dunleavy","year":"2010","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/his.14798","article-title":"Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: Diagnostic and prognostic implications","volume":"81","author":"Baptista","year":"2022","journal-title":"Histopathology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(03)00983-5","article-title":"Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS","volume":"4","author":"Franceschi","year":"2003","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1182\/blood-2014-11-599951","article-title":"The tumor virus landscape of AIDS-related lymphomas","volume":"125","author":"Arvey","year":"2015","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1182\/blood-2018-11-852442","article-title":"Kaposi sarcoma-associated herpesvirus\/human herpesvirus 8-associated lymphoproliferative disorders","volume":"133","author":"Oksenhendler","year":"2019","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1158\/1078-0432.CCR-11-3169","article-title":"Epstein-Barr Virus Infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell lymphoma","volume":"18","author":"Chao","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabil\u00edstic classification tool for gen\u00e8tic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: A Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2013-03-488171","article-title":"The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies","volume":"122","author":"Liapis","year":"2013","journal-title":"Blood"},{"key":"ref_52","first-page":"605","article-title":"AIDS-related non-Hodgkin lymphoma: Still a problem in the era of HAART","volume":"14","author":"Aboulafia","year":"2004","journal-title":"AIDS Read"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0959-8049(01)00111-3","article-title":"Clinical aspects and management of AIDS-related lymphoma","volume":"37","author":"Sparano","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.13519","article-title":"Human immunodeficiency virus-related non-Hodgkin\u2019s lymphoma","volume":"93","author":"Ribera","year":"2008","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/bjh.13998","article-title":"Central nervous system involvement in AIDS-related lymphomas","volume":"173","author":"Barta","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated cancers and related diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2012-04-423095","article-title":"Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination","volume":"120","author":"Benevolo","year":"2012","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199706053362304","article-title":"Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin\u2019s lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group","volume":"336","author":"Kaplan","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/00002030-200008180-00001","article-title":"Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy","volume":"14","author":"Tirelli","year":"2000","journal-title":"AIDS"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2001.19.8.2171","article-title":"Chemotherapy for human immunodeficiency virus-associated non-Hodgkin\u2019s lymphoma in combination with highly active antiretroviral therapy","volume":"19","author":"Ratner","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2005-09-3600","article-title":"AIDS-related non-Hodgkin lymphoma: Final analysis of 485 patients treated with risk-adapted intensive chemotherapy","volume":"107","author":"Mounier","year":"2006","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/blood-2002-11-3589","article-title":"Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: Impact of antiretroviral therapy suspension and tumor biology","volume":"101","author":"Little","year":"2003","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","article-title":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","volume":"115","author":"Sparano","year":"2010","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/cncr.26723","article-title":"Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma","volume":"118","author":"Barta","year":"2012","journal-title":"Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.22275","article-title":"Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: A pooled analysis of 15 prospective studies","volume":"87","author":"Castillo","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2004.08.195","article-title":"Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin\u2019s lymphoma: An Eastern Cooperative Oncology Group Trial (E1494)","volume":"22","author":"Sparano","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/bjc.1996.360","article-title":"A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin\u2019s lymphoma: A British National Lymphoma Investigation report","volume":"74","author":"Linch","year":"1996","journal-title":"Br. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1054\/bjoc.2000.1566","article-title":"Survival in patients with intermediate or high grade non-Hodgkin\u2019s lymphoma: Meta-analysis of randomized studies comparing third generation regimens with CHOP","volume":"84","author":"Messori","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2004-08-3300","article-title":"Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV- associated non-Hodgkin lymphoma: Pooled results from 3 phase 2 trials","volume":"105","author":"Spina","year":"2005","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2011-08-373738","article-title":"How I treat HIV-associated lymphoma","volume":"119","author":"Dunleavy","year":"2012","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","article-title":"Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin\u2019s lymphoma","volume":"24","author":"Gabarre","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2141.2007.06943.x","article-title":"Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: Results of a phase II trial","volume":"140","author":"Ribera","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2141.2012.09046.x","article-title":"Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP","volume":"157","author":"Ribera","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: A pooled analysis of 1546 patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1200\/JCO.2012.42.4648","article-title":"Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047","volume":"31","author":"Levine","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/QAD.0b013e32834f30fa","article-title":"Treatment of AIDS-related lymphomas: Rituximab is beneficial even in severely immunosuppressed patients","volume":"26","author":"Wyen","year":"2012","journal-title":"AIDS"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2000.18.21.3633","article-title":"Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH","volume":"18","author":"Gutierrez","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: Clinical outcomes of the phase III Intergroup Trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1182\/blood-2009-02-202762","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: Long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors","volume":"114","author":"Re","year":"2009","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2008.18.2683","article-title":"Autologous stem-cell transplantation in patients with HIV-related lymphoma","volume":"27","author":"Balsalobre","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.bbmt.2010.03.019","article-title":"HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL)","volume":"16","author":"Krishnan","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1182\/blood-2008-12-195388","article-title":"Comparable survival between HIV+ and HIV\u2212 non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation","volume":"113","author":"Balsalobre","year":"2009","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1097\/QAD.0000000000002209","article-title":"Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders","volume":"33","author":"Kwon","year":"2019","journal-title":"AIDS"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1002\/cncr.32411","article-title":"Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma","volume":"125","author":"Abramson","year":"2019","journal-title":"Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","article-title":"Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis","volume":"13","author":"Abbasi","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/COH.0000000000000320","article-title":"Cancer care disparities in people with HIV in the United States","volume":"12","author":"Suneja","year":"2017","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1046\/j.1365-2141.2001.02656.x","article-title":"Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin\u2019s lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone","volume":"112","author":"Navarro","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1097-0142(20010101)91:1<155::AID-CNCR20>3.0.CO;2-B","article-title":"Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma","volume":"91","author":"Vaccher","year":"2001","journal-title":"Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/00002030-200307040-00013","article-title":"Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma","volume":"17","author":"Hoffmann","year":"2003","journal-title":"AIDS"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/cncr.21759","article-title":"Acquired immunodeficiency syndrome-related lymphoma: Simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival\u2013results of the German Multicenter Trial","volume":"106","author":"Weiss","year":"2006","journal-title":"Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1080\/10428194.2017.1403597","article-title":"Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: A comparison within one prospective trial AMC034","volume":"59","author":"Tan","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Zolopa, A., Andersen, J., Powderly, W., Sanchez, A., Sanne, I., Suckow, C., Hogg, E., and Komarow, L. (2009). Early antiretroviral therapy reduces AIDS progression\/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005575"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2165\/00003088-200443050-00003","article-title":"Pharmacokinetic Enhancement of Protease Inhibitor Therapy","volume":"43","author":"Kin","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/phar.1237","article-title":"Cobicistat: A New Boost for the Treatment of Human Immunodeficiency Virus Infection","volume":"33","author":"Sha","year":"2013","journal-title":"Pharmacotherapy"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s11096-018-0620-1","article-title":"Outcome Effects of Antiretroviral Drug Combinations in HIV-Positive Patients with Chemotherapy for Lymphoma: A Retrospective Analysis","volume":"40","author":"Sombogaard","year":"2018","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/hiv.12624","article-title":"Survival in HIV-Infected Patients with Lymphoma According to the Choice of Antiretroviral Treatment: An Observational Multicentre Study","volume":"19","author":"Rusconi","year":"2018","journal-title":"HIV Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"O672","DOI":"10.1111\/1469-0691.12589","article-title":"Efficacy and Safety of Antiretrovirals in HIV-Infected Patients with Cancer","volume":"20","author":"Torres","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1200\/JCO.2005.05.128","article-title":"Potential Antiretroviral Drug Interactions with Cyclophosphamide, Doxorubicin, and Etoposide","volume":"23","author":"Bower","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s11096-009-9323-y","article-title":"Paralytic Ileus Possibly Associated with Interaction between Ritonavir\/Lopinavir and Vincristine","volume":"31","author":"Santucci","year":"2009","journal-title":"Pharm. World Sci. PWS"},{"key":"ref_103","first-page":"805","article-title":"Use of a Physiologically Based Pharmacokinetic Model to Simulate Drug-Drug Interactions between Antineoplastic and Antiretroviral Drugs","volume":"72","author":"Rajoli","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/jac\/dks404","article-title":"Rilpivirine: A New Non-Nucleoside Reverse Transcriptase Inhibitor","volume":"68","author":"Sharma","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40261-020-00934-2","article-title":"Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions","volume":"40","author":"Khalilieh","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/IDR.S40168","article-title":"Long-Term Efficacy and Safety of Raltegravir in the Management of HIV Infection","volume":"7","author":"Liedtke","year":"2014","journal-title":"Infect. Drug Resist."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1358\/dot.2019.55.11.3068796","article-title":"Bictegravir, a Novel Integrase Inhibitor for the Treatment of HIV Infection","volume":"55","author":"Zeuli","year":"2019","journal-title":"Drugs Today Barc."},{"key":"ref_109","unstructured":"(2023, January 10). Lenacapavir Prescribing Information. Available online: www.ema.europa.eu\/en\/documents\/product-information\/sunlenca-epar-product-information_en.pdf."},{"key":"ref_110","unstructured":"(2023, January 10). Fostemsavir Prescribing Information. Available online: www.ema.europa.eu\/en\/documents\/product-information\/rukobia-epar-product-information_en.pdf."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/QAD.0000000000002438","article-title":"The Effect of Multivitamins and Polyvalent Cations on Virologic Suppression with Integrase Strand Transfer Inhibitors","volume":"34","author":"James","year":"2020","journal-title":"AIDS"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40121-020-00307-4","article-title":"HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir","volume":"9","author":"Rock","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"986","DOI":"10.6004\/jnccn.2018.0066","article-title":"Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Reid","year":"2018","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2352-3026(20)30115-0","article-title":"Treatment management of haematological malignancies in people living with HIV","volume":"7","author":"Re","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_116","unstructured":"Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents (2022, November 13). Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America, Available online: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-oi\/guidelines-adult-adolescent-oi.pdf."},{"key":"ref_117","unstructured":"European AIDS Clinical Society (2022, November 13). European AIDS Clinical Society Guidelines (Version 9.1). Available online: https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html."},{"key":"ref_118","unstructured":"Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV (2023, April 13). Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-opportunistic-infection."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.1998.16.11.3601","article-title":"Prognostic factors in the treatment of human immunodeficiency virus associated non-Hodgkin\u2019s lymphoma: Analysis of AIDS Clinical Trials Group protocol 142-low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases","volume":"16","author":"Straus","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0002-9343(93)90259-R","article-title":"Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group","volume":"95","author":"Gisselbrecht","year":"1993","journal-title":"Am. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993). A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N. Engl. J. Med., 329, 987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3324\/haematol.2014.111112","article-title":"A new prognostic score for AIDS-related lymphomas in the rituximab-era","volume":"99","author":"Barta","year":"2014","journal-title":"Haematologica"},{"key":"ref_124","first-page":"508","article-title":"International prognostic index is the best prognostic factor for survival in patients withAIDS-related non-Hodgkin\u2019s lymphoma treated with CHOP. A multivariate study of 46 patients","volume":"83","author":"Navarro","year":"1998","journal-title":"Haematologica"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/(SICI)1097-0142(19991201)86:11<2391::AID-CNCR29>3.0.CO;2-0","article-title":"The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma","volume":"86","author":"Rossi","year":"1999","journal-title":"Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1200\/JCO.2005.02.9355","article-title":"Prognostic factors in HIV-related diffuse large-cell lymphoma: Before versus after highly active antiretroviral therapy","volume":"23","author":"Lim","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAI.0b013e31802bb5d0","article-title":"Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors","volume":"44","author":"Miralles","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1002\/cncr.23911","article-title":"Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database","volume":"113","author":"Kho","year":"2008","journal-title":"Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/bjh.14489","article-title":"Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): The addition of \u03b22-microglobulin yields a more accurate GELTAMO-IPI","volume":"176","author":"Montalban","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16263","article-title":"New prognosis score including absolute lymphocyte\/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)","volume":"188","author":"Bento","year":"2020","journal-title":"Br. J. Haematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/12\/3191\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:55:16Z","timestamp":1760126116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/12\/3191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":131,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["cancers15123191"],"URL":"https:\/\/doi.org\/10.3390\/cancers15123191","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]}}}